Recent Analysts’ Ratings Changes for Evommune (EVMN)

Several analysts have recently updated their ratings and price targets for Evommune (NYSE: EVMN):

• 5/11/2026 – Evommune had its price target raised by Morgan Stanley from $54.00 to $55.00. They now have an “overweight” rating on the stock.
• 5/10/2026 – Evommune was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/2/2026 – Evommune was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/1/2026 – Evommune is now covered by Stifel Nicolaus. They set a “buy” rating and a $54.00 price target on the stock.
• 4/10/2026 – Evommune had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $48.00 price target on the stock.
• 4/7/2026 – Evommune is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $50.00 price target on the stock.
• 3/18/2026 – Evommune had its price target lowered by HC Wainwright from $65.00 to $50.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Evommune was upgraded by Clear Str Llc to “strong-buy”.

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.